Clarity Pharmaceuticals’ Post

📅Lunch and Learn with Us! Join us at #AACR24: https://ow.ly/WlE450R9ExY Dive deep into precision oncology with advancements powered by Droplet Digital PCR (ddPCR) over the last decade. Dr. Pestano from Biodesix details innovative blood tests to aid the diagnosis and management of lung cancer. Discover the potential of ddPCR for ctDNA analysis and how Biodesix is collaborating to overcome regulatory obstacles impeding widespread clinical adoption of ctDNA testing. #CancerResearch #ctDNA #Lungcancer

【Medical students contribute in significant cancer research discovery】 A team from the Department of Anatomical and Cellular Pathology in CU Medicine that also includes two medical students has developed a unified molecular classification of cancer-associated fibroblasts (CAFs) on a pan-cancer scale, a breakthrough that promises to enhance the understanding of cancer progression and treatment. CAFs are critical components of the tumour microenvironment and play a dual role in either promoting or hindering cancer growth. Employing a comprehensive single-cell transcriptomic atlas encompassing 12 solid tumour types, the CU Medicine research team identified four distinct molecular clusters of CAFs that are observed across various solid tumour types: progenitor CAF (proCAF), inflammatory CAF (iCAF), myofibroblastic CAF (myCAF) and matrix-producing CAF (matCAF). This discovery is a major step forward in understanding the complex dynamics of the tumour microenvironment. The molecular classification has broad applicability in cancer research. Brian Chan and Wilson Mui, both year 5 students in the Global Physician-Leadership (GPS) stream, together with postdoctoral fellow Dr Chen Bonan, administered this study under the supervision of professors from the Department of Anatomical and Cellular Pathology. This is the students’ second published study with the team. The landmark findings have been published in leading journal Clinical and Translational Medicine. Details: https://bit.ly/42GQFCh Full article: https://bit.ly/4bKwlnq #CUMedicine #CancerResearch #MedStudents #GPS

NEWS UPDATE: Hollings Cancer Center researcher Jennifer Dahne, Ph.D., co-director of the remote and virtual trials program at the South Carolina Clinical & Translational Research Institute, hears more than any other as she consults with clinical researchers about how to set up remote trials, also known as decentralized trials. Will these trials overcome the barriers that make it difficult for minority and underserved populations to participate in clinical trials? It's also a question she often discusses with her peers at other academic medical centers that are also home to Clinical and Translational Science Award hubs. #healthcareprofessional #indorivclinical #healthcare #medicalresearch #biobanking #medical #healthylife #medicalstudent #biobank #researchdevelopment #medicaleducation #bodyhealthy #indoriv #healthcoach #medicalscience #medicalstudents #clinical #clinicaltrials #clinicalpilates #clinicalpractice #clinicalresearch #clinicallyproven #clinicalnutrition #clinicalhypnotherapy #clinicalpsychology

This week DIVINCELL and Aanastra Inc will be at the American Association for Cancer Research Meeting 2024 in San Diego, CA. https://lnkd.in/g6P3g2CD Join Us on April 7th and 10th, We will be presenting our recent RNA Therapeutic work on : ▶ “In vivo rescue of p53 tumor suppressor function with ADGN-531 across Pan-p53 alterations” ▶ “Selective deletion of the KRAS mutant gene with ADGN-121 and ADGN-122 peptide-RNA nanoparticles: A new strategy to overcome acquired resistance to KRASG12C and KRASG12D small molecule inhibitors” ▶ “Peptide-mRNA complex mediated restoration of BRCA-1 tumor suppressor function in BRCA-1 mutated cancers as a new therapeutic strategy” #p53 #KRAS #PARPi #CRISPR #nanotechnology #drugdelivery #mRNA #cancer #AACR #BRCA-1 #geneediting

The Charcot-Marie-Tooth Association (CMTA) Leads in Cutting-Edge CMT Research and in Patient Recruitment The CMTA is the global leader in innovative approaches to understanding Charcot-Marie-Tooth disease (CMT) while working to develop treatments and ultimately a cure for this disease, and our global community-led mission positions us as the leader in patient recruitment.  Through our Strategy to Accelerate Research (STAR), we seek out scientists who are on the cutting edge of CMT science. Esther Wolfs, PhD, head of FIERCE Laboratory at Hasselt University in Belgium, is one such scientist. With CMTA funding and patient recruitment support, Dr. Wolfs and colleagues are developing a new model of CMT1A, the most common form of CMT, from Human Dental Pulp Stem Cells (hDPSC) derived from wisdom teeth. Through our Patients as Partners in Research initiative which is the largest single-source registry of CMT patients in the world, we are able to engage CMT community members no matter where they live for participation in this research as potential wisdom teeth donors.  Our innovative approach through STAR and Patients as Partners in Research is paving the way for potential treatments and is getting us closer to a cure. Learn more about this unique research opportunity and discover how you, too, can collaborate with the CMTA: https://lnkd.in/eXHuRsxZ Let's advance CMT research together! #CMTASTAR #CMTResearch

🐈 🐈⬛ and I attended grand rounds today! Grand rounds are 🔥 dynamic, educational sessions in the medical field that bring together healthcare professionals to discuss complex cases, share expertise, and stay updated on the latest advancements in patient care. 🩺💡 These gatherings provide a platform for interdisciplinary collaboration, fostering a vibrant learning environment. 🤝📚 In the realm of hematology oncology, grand rounds take on a unique significance. They serve as a hub for hematologists and oncologists to delve into intricate cases of blood disorders and cancer. 💉🦠 These sessions feature riveting discussions about cutting-edge treatments, precision medicine, and emerging therapies, all aimed at improving the lives of patients battling these diseases. 🚀💪 These aren't your typical lectures; they're engaging forums where real patient stories and clinical puzzles come to life. 🧩💬 Whether you're a young medical professional seeking inspiration or a seasoned expert looking to stay at the forefront of your field, rounds are a must-attend event (at least a few times throughout your cancer research journey). 🏥🔬 Whimsically me, Elizabeth the Scientist 👩🏽🔬 #MedEd #HematologyOncology #MedicalAdvancements

Faranak Fattahi, PhD is one of CMTA-STAR's 40 Under 40! ⭐ When the CMTA implemented its Strategy to Accelerate Research in 2008, a key component was enlisting investigators and scientists from an international body of the world’s most accomplished medical pioneers. Our integrated team of top scientists and industry partners working together toward a common goal is what sets the CMTA-STAR program apart and what drives its remarkable success. Today, the next generation of researchers—our 40 Under 40—is making significant strides in reshaping our comprehension of CMT. Their passion, expertise and relentless pursuit of scientific breakthroughs and high-quality patient care play a pivotal role in driving progress towards effective treatments and, ultimately, a more promising future for the CMT community. Fattahi’s research focuses on directing the differentiation of human pluripotent stem cells toward peripheral neurons and glia and their application in disease modeling, drug discovery and regenerative medicine. Her team recently succeeded in generating the myelinating cells commonly known as Schwann cells, marking a significant milestone in their research. These advanced stem cell-based models are instrumental in deciphering intricate disease mechanisms and identifying potential therapeutic targets for complex peripheral neuropathies such as CMT. University of California, San Francisco Learn about all of the CMTA-STAR's 40 under 40: https://lnkd.in/eVDtmGDy

New perspectives in cancer treatment are opening with the RESPECT registry conducted by CIRSE 💡 ✅ RESPECT is a European-wide, prospective, observational cohort study collecting data from patients with primary or secondary liver cancer treated by percutaneous electrochemotherapy (#pECT) using the CLINIPORATOR device (#Igea). ✅ We are happy that our partners VILNIUS UNIVERSITY HOSPITAL #SANTARA CLINICS is participating in RESPECT registro. Congratulations to doctor Donatas Jocius, who is leading registry. ✅ ELECTROCHEMOTHERAPY (#ECT) IS A MINIMALLY INVASIVE LOCOREGIONAL THERAPY FOR THE TREATMENT OF SOLID TUMOURS. Tumor lesions of different origins can be effectively treated with ECT. It is #effective at different disease stages, is generally well tolerated and can be performed subsequently or concurrently with other treatments. #oncology #interventionalradiology #interventionaloncology #electrochemotherapy #igea #ambercellsolutions https://lnkd.in/dUJ7FMQ7

Our latest research paper, "Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy," uncovers groundbreaking insights into the management of cancer-associated venous thromboembolism (VTE). Cancer patients face a unique challenge, where VTE ranks as the second-leading cause of mortality. Cancer heightens the risks of both thrombosis and bleeding. Managing VTE in this context is undeniably complex. But here's the good news: recent translational research has unearthed the connection between inflammatory cytokines and cancer's growth and progression. Our study shines a light on the crucial role of anticoagulation therapy in this scenario. Here's the link to the research paper: https://lnkd.in/dHUn359S Subscribe to our newsletter, link here: https://lnkd.in/diUdv3CV As cardio-oncology care is a growing field, there is a need for proper fellowship programs to train cardiologists in cancer-cardiovascular care. Additionally, dedicated and continuous efforts should be made to coordinate medical education and training to promote clinical research in cardio-oncology. Sbarro Health Research Organization Temple University College of Science and Technology Università degli Studi di Siena #SHRO #SbarroInstitute #AntonioGiordano #MadeAtSHRO #DiscoveredAtSHRO #EndCancer #CancerResearch #malignancy #InflammationAndCancer #drantoniogiordano #VascularThrombosis #Health #HealthResearch #MedicalResearch #CancerAndInflammation #ThromboticDiseases #MedicalBreakthrough #ScientificDiscovery #ResearchPaper

Delighted to share insights from my INTERACT-EUROPE Showcase event speech, centred on European Association of Urology's Perspective on turning vision into reality for inter-speciality cancer education. Acknowledging the oncology workforce in crisis and the strong need for patient-centred care. Strategic focus, emphasising quality over quantity. Prioritise topics where the curriculum can make the most significant impact. Extend the curriculum into pre-professional education programmes, shaping a new generation of healthcare professionals with a holistic perspective and fostering a deep understanding of patient care for long-term impact. Measuring success beyond clinical outcomes. Patient satisfaction and the quality of the patient-provider relationship emerge as key metrics. To achieve this, engaging patient groups at every step is paramount. Their insights prove invaluable in making real, impactful changes. #europeancancersummit #INTERACT-Europe #EuropeBeatingCancer